Christina Aquilante
Concepts (344)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Pharmacogenetics | 27 | 2022 | 149 | 5.890 |
Why?
| Pharmacogenomic Testing | 13 | 2022 | 54 | 4.640 |
Why?
| Thiazolidinediones | 8 | 2016 | 146 | 2.940 |
Why?
| Aryl Hydrocarbon Hydroxylases | 10 | 2014 | 43 | 2.610 |
Why?
| Heart Transplantation | 8 | 2021 | 672 | 2.390 |
Why?
| Polymorphism, Genetic | 17 | 2019 | 641 | 2.310 |
Why?
| Precision Medicine | 9 | 2024 | 354 | 1.710 |
Why?
| Polymorphism, Single Nucleotide | 10 | 2021 | 2057 | 1.560 |
Why?
| Hypoglycemic Agents | 11 | 2020 | 1031 | 1.560 |
Why?
| Health Personnel | 4 | 2021 | 578 | 1.540 |
Why?
| Transplant Recipients | 5 | 2021 | 148 | 1.350 |
Why?
| Blood Pressure | 8 | 2020 | 1656 | 1.230 |
Why?
| Organ Transplantation | 2 | 2020 | 164 | 1.220 |
Why?
| Cytochrome P-450 CYP2D6 | 4 | 2022 | 25 | 1.140 |
Why?
| Metabolic Syndrome | 4 | 2016 | 392 | 1.130 |
Why?
| Graft Rejection | 2 | 2021 | 548 | 1.060 |
Why?
| Pharmacists | 3 | 2022 | 235 | 1.030 |
Why?
| Cytochrome P-450 CYP3A | 6 | 2016 | 60 | 0.850 |
Why?
| Gemfibrozil | 2 | 2013 | 10 | 0.840 |
Why?
| Sulfonylurea Compounds | 3 | 2018 | 44 | 0.810 |
Why?
| Leukopenia | 1 | 2021 | 26 | 0.810 |
Why?
| Adiponectin | 2 | 2016 | 224 | 0.810 |
Why?
| Hepatocyte Nuclear Factor 1-alpha | 1 | 2021 | 16 | 0.810 |
Why?
| Hypolipidemic Agents | 2 | 2013 | 86 | 0.790 |
Why?
| Mycophenolic Acid | 1 | 2021 | 79 | 0.780 |
Why?
| Desogestrel | 5 | 2021 | 41 | 0.760 |
Why?
| Organic Anion Transporters | 2 | 2011 | 19 | 0.750 |
Why?
| Biological Specimen Banks | 2 | 2024 | 103 | 0.740 |
Why?
| Genotype | 16 | 2021 | 1870 | 0.740 |
Why?
| Hypertension | 3 | 2020 | 1199 | 0.710 |
Why?
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2013 | 387 | 0.700 |
Why?
| Adult | 41 | 2022 | 31324 | 0.700 |
Why?
| Middle Aged | 38 | 2021 | 27510 | 0.680 |
Why?
| Prescription Drugs | 2 | 2020 | 113 | 0.670 |
Why?
| Cytochrome P-450 CYP2C8 | 7 | 2014 | 15 | 0.670 |
Why?
| Cardiologists | 1 | 2018 | 40 | 0.660 |
Why?
| Humans | 73 | 2024 | 118251 | 0.640 |
Why?
| Dipeptidyl-Peptidase IV Inhibitors | 2 | 2021 | 44 | 0.630 |
Why?
| Physicians | 3 | 2021 | 792 | 0.620 |
Why?
| HIV Protease Inhibitors | 4 | 2016 | 64 | 0.610 |
Why?
| Female | 50 | 2021 | 61261 | 0.600 |
Why?
| Decision Support Systems, Clinical | 1 | 2020 | 176 | 0.600 |
Why?
| Male | 46 | 2021 | 57474 | 0.600 |
Why?
| Academic Medical Centers | 1 | 2020 | 422 | 0.590 |
Why?
| Ritonavir | 4 | 2012 | 70 | 0.590 |
Why?
| Heart Failure | 4 | 2017 | 1967 | 0.570 |
Why?
| Polypharmacy | 1 | 2017 | 75 | 0.560 |
Why?
| Warfarin | 3 | 2008 | 139 | 0.560 |
Why?
| Lectins | 1 | 2016 | 49 | 0.550 |
Why?
| Attitude of Health Personnel | 2 | 2020 | 990 | 0.550 |
Why?
| Cytochrome P-450 CYP2C19 | 5 | 2022 | 21 | 0.540 |
Why?
| Nonprescription Drugs | 1 | 2016 | 67 | 0.540 |
Why?
| Antiviral Agents | 1 | 2021 | 653 | 0.530 |
Why?
| Tacrolimus | 1 | 2016 | 149 | 0.530 |
Why?
| Medicare | 1 | 2020 | 664 | 0.510 |
Why?
| Cytochrome P-450 Enzyme System | 2 | 2006 | 111 | 0.510 |
Why?
| Contraceptive Agents, Female | 3 | 2020 | 65 | 0.500 |
Why?
| Death, Sudden, Cardiac | 3 | 2021 | 166 | 0.490 |
Why?
| Pediatrics | 2 | 2021 | 980 | 0.480 |
Why?
| Blood Pressure Determination | 1 | 2014 | 133 | 0.460 |
Why?
| Arrhythmias, Cardiac | 3 | 2021 | 277 | 0.460 |
Why?
| Chemokine CXCL5 | 3 | 2012 | 11 | 0.450 |
Why?
| Heptanoic Acids | 1 | 2013 | 62 | 0.440 |
Why?
| Pyrazines | 1 | 2013 | 72 | 0.430 |
Why?
| Diabetes Mellitus, Type 2 | 5 | 2020 | 2159 | 0.420 |
Why?
| Resistin | 2 | 2010 | 13 | 0.420 |
Why?
| Pravastatin | 1 | 2011 | 29 | 0.420 |
Why?
| Pyrroles | 1 | 2013 | 188 | 0.410 |
Why?
| Pharmaceutical Preparations | 3 | 2009 | 168 | 0.410 |
Why?
| Triazoles | 1 | 2013 | 128 | 0.410 |
Why?
| Cross-Sectional Studies | 8 | 2020 | 4521 | 0.410 |
Why?
| Health Knowledge, Attitudes, Practice | 4 | 2021 | 1183 | 0.400 |
Why?
| Dobutamine | 3 | 2008 | 36 | 0.400 |
Why?
| Retrospective Studies | 12 | 2021 | 12929 | 0.380 |
Why?
| Managed Care Programs | 2 | 2022 | 135 | 0.370 |
Why?
| Antidepressive Agents | 2 | 2022 | 189 | 0.370 |
Why?
| Aged | 17 | 2021 | 19594 | 0.360 |
Why?
| Mixed Function Oxygenases | 2 | 2008 | 37 | 0.350 |
Why?
| Drug Interactions | 5 | 2017 | 351 | 0.350 |
Why?
| DNA | 1 | 2016 | 1385 | 0.350 |
Why?
| Chromatography, Liquid | 1 | 2010 | 353 | 0.340 |
Why?
| Young Adult | 13 | 2021 | 10731 | 0.330 |
Why?
| Polymerase Chain Reaction | 3 | 2006 | 1004 | 0.330 |
Why?
| Sulfonamides | 1 | 2011 | 444 | 0.320 |
Why?
| Drug Prescriptions | 4 | 2021 | 248 | 0.320 |
Why?
| Health | 1 | 2008 | 80 | 0.320 |
Why?
| Cytokines | 1 | 2016 | 1880 | 0.320 |
Why?
| Chemokine CCL2 | 1 | 2008 | 124 | 0.310 |
Why?
| Blood Glucose | 3 | 2016 | 1936 | 0.310 |
Why?
| Time Factors | 8 | 2020 | 6368 | 0.310 |
Why?
| Drug Implants | 4 | 2021 | 72 | 0.310 |
Why?
| Mass Spectrometry | 1 | 2010 | 670 | 0.300 |
Why?
| Immunosuppressive Agents | 4 | 2021 | 682 | 0.300 |
Why?
| Heart Rate | 3 | 2008 | 729 | 0.300 |
Why?
| Receptors, Adrenergic, beta | 1 | 2008 | 142 | 0.300 |
Why?
| Matrix Metalloproteinase 8 | 1 | 2006 | 8 | 0.300 |
Why?
| Haplotypes | 5 | 2013 | 474 | 0.290 |
Why?
| Sequence Analysis, DNA | 4 | 2012 | 748 | 0.290 |
Why?
| Vitamin K Epoxide Reductases | 3 | 2020 | 12 | 0.280 |
Why?
| Metoprolol | 1 | 2006 | 37 | 0.280 |
Why?
| Blood Coagulation Factors | 1 | 2006 | 42 | 0.270 |
Why?
| Clinical Laboratory Techniques | 1 | 2006 | 89 | 0.270 |
Why?
| Autonomic Nervous System | 1 | 2006 | 66 | 0.270 |
Why?
| Clinical Protocols | 2 | 2017 | 234 | 0.260 |
Why?
| Administration, Oral | 4 | 2016 | 753 | 0.260 |
Why?
| Models, Biological | 1 | 2013 | 1701 | 0.260 |
Why?
| Echocardiography | 1 | 2008 | 556 | 0.260 |
Why?
| Cross-Over Studies | 3 | 2013 | 456 | 0.260 |
Why?
| Anticoagulants | 2 | 2008 | 555 | 0.260 |
Why?
| Prospective Studies | 6 | 2020 | 6443 | 0.260 |
Why?
| Genetic Variation | 3 | 2019 | 912 | 0.250 |
Why?
| Echocardiography, Stress | 1 | 2004 | 21 | 0.250 |
Why?
| Polymorphism, Restriction Fragment Length | 1 | 2004 | 64 | 0.250 |
Why?
| Adrenergic beta-Antagonists | 1 | 2006 | 301 | 0.240 |
Why?
| Carrier Proteins | 1 | 2008 | 725 | 0.240 |
Why?
| Cohort Studies | 7 | 2021 | 5078 | 0.240 |
Why?
| Biotransformation | 2 | 2013 | 52 | 0.230 |
Why?
| Cytochrome P-450 CYP2C9 | 4 | 2019 | 18 | 0.230 |
Why?
| Metformin | 1 | 2007 | 293 | 0.230 |
Why?
| Alleles | 6 | 2012 | 829 | 0.230 |
Why?
| Waist Circumference | 2 | 2016 | 130 | 0.220 |
Why?
| Gene Frequency | 4 | 2013 | 511 | 0.210 |
Why?
| Follow-Up Studies | 4 | 2021 | 4574 | 0.210 |
Why?
| Antimalarials | 2 | 2013 | 24 | 0.210 |
Why?
| Clinical Trials as Topic | 1 | 2006 | 964 | 0.210 |
Why?
| Drug Dosage Calculations | 1 | 2020 | 21 | 0.190 |
Why?
| Calcineurin Inhibitors | 1 | 2021 | 60 | 0.190 |
Why?
| Pharmacogenomic Variants | 2 | 2021 | 35 | 0.190 |
Why?
| Antibiotics, Antineoplastic | 1 | 2021 | 114 | 0.190 |
Why?
| Egypt | 1 | 2020 | 10 | 0.190 |
Why?
| Cytomegalovirus | 1 | 2021 | 144 | 0.190 |
Why?
| Atazanavir Sulfate | 3 | 2016 | 41 | 0.190 |
Why?
| Area Under Curve | 2 | 2013 | 293 | 0.180 |
Why?
| Aged, 80 and over | 4 | 2017 | 6541 | 0.180 |
Why?
| No-Show Patients | 1 | 2019 | 1 | 0.180 |
Why?
| Menstruation Disturbances | 1 | 2019 | 12 | 0.180 |
Why?
| Hemodynamics | 1 | 2004 | 1002 | 0.180 |
Why?
| Colorado | 3 | 2024 | 4178 | 0.180 |
Why?
| Blood Pressure Monitoring, Ambulatory | 1 | 2020 | 66 | 0.180 |
Why?
| Lipids | 2 | 2016 | 591 | 0.180 |
Why?
| Cytochrome P450 Family 3 | 1 | 2019 | 2 | 0.180 |
Why?
| Brain Chemistry | 1 | 2000 | 118 | 0.170 |
Why?
| United States | 8 | 2021 | 12488 | 0.170 |
Why?
| Smoking | 1 | 2006 | 1478 | 0.170 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2013 | 301 | 0.170 |
Why?
| Oligopeptides | 2 | 2012 | 250 | 0.170 |
Why?
| Double-Blind Method | 2 | 2016 | 1683 | 0.170 |
Why?
| Morphine | 1 | 2000 | 132 | 0.170 |
Why?
| Body Weight | 2 | 2016 | 923 | 0.170 |
Why?
| Patients | 1 | 2020 | 174 | 0.160 |
Why?
| Sitagliptin Phosphate | 2 | 2021 | 30 | 0.160 |
Why?
| Child Health Services | 1 | 2020 | 177 | 0.160 |
Why?
| Body Mass Index | 3 | 2019 | 2074 | 0.160 |
Why?
| Bariatric Surgery | 1 | 2021 | 166 | 0.160 |
Why?
| Progesterone | 1 | 2019 | 242 | 0.160 |
Why?
| Ventricular Dysfunction | 1 | 2018 | 15 | 0.160 |
Why?
| Dose-Response Relationship, Drug | 3 | 2016 | 1937 | 0.160 |
Why?
| Apyrase | 1 | 2017 | 13 | 0.150 |
Why?
| Pyridines | 2 | 2012 | 436 | 0.150 |
Why?
| Healthy Volunteers | 2 | 2019 | 194 | 0.150 |
Why?
| Organophosphonates | 2 | 2008 | 94 | 0.150 |
Why?
| Depression | 2 | 2022 | 1133 | 0.150 |
Why?
| Anti-HIV Agents | 2 | 2016 | 662 | 0.140 |
Why?
| Psychiatry | 1 | 2020 | 200 | 0.140 |
Why?
| DNA Primers | 3 | 2006 | 532 | 0.140 |
Why?
| Circadian Rhythm | 1 | 2020 | 394 | 0.140 |
Why?
| Pyrophosphatases | 1 | 2016 | 22 | 0.140 |
Why?
| Chronic Disease | 2 | 2017 | 1630 | 0.140 |
Why?
| Treatment Outcome | 6 | 2021 | 9319 | 0.140 |
Why?
| GPI-Linked Proteins | 1 | 2016 | 56 | 0.140 |
Why?
| Electronic Health Records | 2 | 2020 | 809 | 0.140 |
Why?
| Cardiology | 1 | 2018 | 272 | 0.140 |
Why?
| Patient Care | 1 | 2016 | 105 | 0.140 |
Why?
| Adenine | 2 | 2008 | 222 | 0.140 |
Why?
| Gene Expression Regulation, Enzymologic | 1 | 2017 | 287 | 0.130 |
Why?
| Ribavirin | 1 | 2016 | 88 | 0.130 |
Why?
| Students, Pharmacy | 1 | 2016 | 99 | 0.130 |
Why?
| HIV Infections | 4 | 2016 | 2454 | 0.130 |
Why?
| Metabolic Clearance Rate | 2 | 2013 | 111 | 0.130 |
Why?
| Therapeutics | 1 | 2015 | 12 | 0.130 |
Why?
| Education, Pharmacy | 1 | 2016 | 130 | 0.130 |
Why?
| beta-Cyclodextrins | 1 | 2015 | 31 | 0.130 |
Why?
| Delivery of Health Care | 1 | 2022 | 862 | 0.130 |
Why?
| Voriconazole | 1 | 2015 | 24 | 0.130 |
Why?
| Renal Replacement Therapy | 1 | 2015 | 70 | 0.130 |
Why?
| Surgical Procedures, Operative | 1 | 2017 | 214 | 0.130 |
Why?
| Patient Education as Topic | 1 | 2019 | 696 | 0.120 |
Why?
| Antigens, CD | 1 | 2017 | 457 | 0.120 |
Why?
| Diltiazem | 1 | 2014 | 22 | 0.120 |
Why?
| Adolescent | 6 | 2021 | 18364 | 0.120 |
Why?
| Antifungal Agents | 1 | 2015 | 134 | 0.120 |
Why?
| Chromosomes, Human, Pair 10 | 1 | 2013 | 19 | 0.120 |
Why?
| Reoperation | 1 | 2016 | 557 | 0.120 |
Why?
| Cardiomyopathies | 1 | 2017 | 298 | 0.120 |
Why?
| Venous Thromboembolism | 1 | 2017 | 233 | 0.120 |
Why?
| Kidney Transplantation | 1 | 2019 | 576 | 0.110 |
Why?
| Half-Life | 1 | 2013 | 147 | 0.110 |
Why?
| Sirolimus | 1 | 2014 | 195 | 0.110 |
Why?
| Medication Adherence | 1 | 2017 | 554 | 0.110 |
Why?
| Liver Transplantation | 1 | 2019 | 843 | 0.110 |
Why?
| Practice Patterns, Physicians' | 1 | 2020 | 1197 | 0.100 |
Why?
| Tissue Distribution | 2 | 2014 | 332 | 0.100 |
Why?
| Darunavir | 1 | 2011 | 17 | 0.100 |
Why?
| Lung Transplantation | 1 | 2014 | 263 | 0.100 |
Why?
| Self Care | 1 | 2014 | 356 | 0.100 |
Why?
| Genetic Association Studies | 1 | 2013 | 355 | 0.100 |
Why?
| Prevalence | 1 | 2017 | 2321 | 0.100 |
Why?
| Acquired Immunodeficiency Syndrome | 1 | 2012 | 219 | 0.090 |
Why?
| Reverse Transcriptase Inhibitors | 2 | 2008 | 80 | 0.090 |
Why?
| Insulin Resistance | 2 | 2010 | 1167 | 0.090 |
Why?
| Patient Discharge | 1 | 2016 | 791 | 0.090 |
Why?
| Cholesterol | 1 | 2011 | 375 | 0.090 |
Why?
| Phenotype | 2 | 2016 | 2937 | 0.090 |
Why?
| Longitudinal Studies | 1 | 2016 | 2491 | 0.090 |
Why?
| Triglycerides | 1 | 2011 | 515 | 0.090 |
Why?
| Leukocytes | 2 | 2012 | 284 | 0.090 |
Why?
| ATP-Binding Cassette Transporters | 1 | 2010 | 125 | 0.090 |
Why?
| Kidney Failure, Chronic | 1 | 2015 | 514 | 0.090 |
Why?
| Lipoproteins | 1 | 2010 | 163 | 0.090 |
Why?
| Surveys and Questionnaires | 1 | 2020 | 4684 | 0.080 |
Why?
| Risk Assessment | 3 | 2020 | 3043 | 0.080 |
Why?
| Databases, Factual | 3 | 2021 | 1196 | 0.080 |
Why?
| Lung Diseases | 1 | 2014 | 709 | 0.080 |
Why?
| Incidence | 2 | 2020 | 2413 | 0.080 |
Why?
| Weight Gain | 2 | 2021 | 485 | 0.070 |
Why?
| Drug Delivery Systems | 1 | 2010 | 306 | 0.070 |
Why?
| Pyrimidinones | 1 | 2007 | 86 | 0.070 |
Why?
| Indinavir | 1 | 2006 | 6 | 0.070 |
Why?
| Cardiovascular Diseases | 2 | 2010 | 1795 | 0.070 |
Why?
| Reproducibility of Results | 1 | 2014 | 2855 | 0.070 |
Why?
| Biomarkers | 3 | 2014 | 3567 | 0.070 |
Why?
| Genetic Techniques | 1 | 2006 | 60 | 0.070 |
Why?
| Cost-Benefit Analysis | 2 | 2012 | 551 | 0.070 |
Why?
| Linear Models | 2 | 2019 | 817 | 0.070 |
Why?
| Lamivudine | 1 | 2006 | 59 | 0.070 |
Why?
| Oxidation-Reduction | 1 | 2009 | 935 | 0.070 |
Why?
| Factor X | 1 | 2006 | 25 | 0.070 |
Why?
| Prothrombin | 1 | 2006 | 21 | 0.070 |
Why?
| Zidovudine | 1 | 2006 | 77 | 0.070 |
Why?
| Factor VII | 1 | 2006 | 22 | 0.070 |
Why?
| International Normalized Ratio | 1 | 2006 | 42 | 0.070 |
Why?
| Chemokines, CXC | 1 | 2006 | 61 | 0.070 |
Why?
| Drug Utilization | 1 | 2007 | 169 | 0.070 |
Why?
| Prognosis | 2 | 2014 | 3424 | 0.070 |
Why?
| C-Reactive Protein | 1 | 2008 | 364 | 0.070 |
Why?
| Base Sequence | 2 | 2006 | 2148 | 0.070 |
Why?
| Delayed-Action Preparations | 1 | 2006 | 161 | 0.070 |
Why?
| Regression Analysis | 1 | 2008 | 984 | 0.070 |
Why?
| Health Care Surveys | 1 | 2007 | 544 | 0.060 |
Why?
| Mathematical Computing | 1 | 2004 | 13 | 0.060 |
Why?
| Gene Expression Regulation | 1 | 2014 | 2435 | 0.060 |
Why?
| Risk Factors | 3 | 2020 | 8958 | 0.060 |
Why?
| Gene Expression | 1 | 2009 | 1482 | 0.060 |
Why?
| Drug Labeling | 1 | 2004 | 44 | 0.060 |
Why?
| Infusions, Intravenous | 1 | 2004 | 379 | 0.060 |
Why?
| Laboratories | 1 | 2004 | 96 | 0.060 |
Why?
| Multidrug Resistance-Associated Proteins | 3 | 2008 | 36 | 0.060 |
Why?
| Kidney | 2 | 2008 | 1351 | 0.060 |
Why?
| Reference Values | 1 | 2004 | 770 | 0.060 |
Why?
| Socioeconomic Factors | 1 | 2007 | 1121 | 0.050 |
Why?
| Linagliptin | 1 | 2021 | 4 | 0.050 |
Why?
| Adamantane | 1 | 2021 | 16 | 0.050 |
Why?
| Administrative Claims, Healthcare | 1 | 2021 | 22 | 0.050 |
Why?
| Dipeptides | 1 | 2021 | 51 | 0.050 |
Why?
| Electronic Prescribing | 1 | 2021 | 4 | 0.050 |
Why?
| Electrocardiography | 1 | 2004 | 555 | 0.050 |
Why?
| Uterine Hemorrhage | 1 | 2021 | 36 | 0.050 |
Why?
| Protective Factors | 1 | 2020 | 90 | 0.040 |
Why?
| Drug Tolerance | 1 | 2000 | 78 | 0.040 |
Why?
| Animals | 3 | 2008 | 33152 | 0.040 |
Why?
| Costs and Cost Analysis | 1 | 2020 | 201 | 0.040 |
Why?
| Treatment Failure | 1 | 2020 | 340 | 0.040 |
Why?
| Homozygote | 2 | 2012 | 189 | 0.040 |
Why?
| Kaplan-Meier Estimate | 1 | 2021 | 840 | 0.040 |
Why?
| Genomics | 1 | 2024 | 668 | 0.040 |
Why?
| Genetic Testing | 1 | 2021 | 388 | 0.040 |
Why?
| Attitude | 1 | 2020 | 230 | 0.040 |
Why?
| Diabetes Mellitus | 1 | 2006 | 939 | 0.040 |
Why?
| Glipizide | 1 | 2018 | 6 | 0.040 |
Why?
| Feasibility Studies | 1 | 2021 | 746 | 0.040 |
Why?
| Antineoplastic Agents | 1 | 2009 | 1967 | 0.040 |
Why?
| Proportional Hazards Models | 1 | 2021 | 1124 | 0.040 |
Why?
| Organic Anion Transport Protein 1 | 2 | 2008 | 6 | 0.040 |
Why?
| Glyburide | 1 | 2018 | 36 | 0.040 |
Why?
| Liver | 1 | 2006 | 1803 | 0.040 |
Why?
| Social Class | 1 | 2019 | 217 | 0.040 |
Why?
| Dexamethasone | 1 | 2000 | 319 | 0.040 |
Why?
| Self-Management | 1 | 2019 | 133 | 0.040 |
Why?
| Self Report | 1 | 2021 | 698 | 0.040 |
Why?
| Anesthetics | 1 | 2017 | 58 | 0.040 |
Why?
| Membrane Transport Proteins | 2 | 2008 | 136 | 0.040 |
Why?
| Tenofovir | 2 | 2008 | 200 | 0.040 |
Why?
| Peru | 1 | 2016 | 59 | 0.030 |
Why?
| Perioperative Care | 1 | 2017 | 131 | 0.030 |
Why?
| Pharmaceutical Services | 1 | 2016 | 79 | 0.030 |
Why?
| Medicaid | 1 | 2020 | 411 | 0.030 |
Why?
| Cause of Death | 1 | 2018 | 379 | 0.030 |
Why?
| Diabetic Angiopathies | 1 | 2018 | 261 | 0.030 |
Why?
| South Africa | 1 | 2016 | 163 | 0.030 |
Why?
| Alternative Splicing | 1 | 2017 | 190 | 0.030 |
Why?
| Indians, North American | 1 | 2021 | 598 | 0.030 |
Why?
| Preoperative Care | 1 | 2017 | 332 | 0.030 |
Why?
| HEK293 Cells | 1 | 2017 | 625 | 0.030 |
Why?
| Rats, Sprague-Dawley | 1 | 2000 | 2434 | 0.030 |
Why?
| Hepatitis C, Chronic | 1 | 2016 | 151 | 0.030 |
Why?
| Everolimus | 1 | 2014 | 64 | 0.030 |
Why?
| Receptors, Steroid | 1 | 2014 | 54 | 0.030 |
Why?
| Demography | 1 | 2014 | 273 | 0.030 |
Why?
| Hypoglycemia | 1 | 2018 | 401 | 0.030 |
Why?
| Age Factors | 1 | 2019 | 2990 | 0.030 |
Why?
| Mental Disorders | 1 | 2020 | 935 | 0.030 |
Why?
| Vasodilator Agents | 1 | 2014 | 328 | 0.030 |
Why?
| Heterozygote | 1 | 2012 | 260 | 0.030 |
Why?
| Rats | 1 | 2000 | 5339 | 0.020 |
Why?
| Genetic Loci | 1 | 2012 | 281 | 0.020 |
Why?
| Insulin | 1 | 2019 | 2157 | 0.020 |
Why?
| Critical Illness | 1 | 2015 | 661 | 0.020 |
Why?
| Algorithms | 2 | 2008 | 1522 | 0.020 |
Why?
| Multivariate Analysis | 1 | 2012 | 1469 | 0.020 |
Why?
| Body Composition | 1 | 2012 | 644 | 0.020 |
Why?
| Genetic Predisposition to Disease | 1 | 2017 | 2262 | 0.020 |
Why?
| Plasma | 1 | 2009 | 194 | 0.020 |
Why?
| Lopinavir | 1 | 2007 | 29 | 0.020 |
Why?
| PubMed | 1 | 2006 | 11 | 0.020 |
Why?
| Ribosomal Proteins | 1 | 2006 | 68 | 0.020 |
Why?
| Antiretroviral Therapy, Highly Active | 1 | 2007 | 258 | 0.020 |
Why?
| Pharmacology | 1 | 2005 | 8 | 0.020 |
Why?
| RNA, Messenger | 1 | 2012 | 2657 | 0.020 |
Why?
| Likelihood Functions | 1 | 2005 | 136 | 0.020 |
Why?
| Molecular Sequence Data | 1 | 2009 | 2855 | 0.020 |
Why?
| Mitochondrial Proteins | 1 | 2006 | 224 | 0.020 |
Why?
| Cardiotonic Agents | 1 | 2005 | 127 | 0.020 |
Why?
| Hemorrhage | 1 | 2008 | 606 | 0.010 |
Why?
| Genome | 1 | 2006 | 271 | 0.010 |
Why?
| Chromosome Mapping | 1 | 2005 | 508 | 0.010 |
Why?
| Drug Therapy, Combination | 1 | 2006 | 964 | 0.010 |
Why?
| Predictive Value of Tests | 1 | 2008 | 1857 | 0.010 |
Why?
| Saccharomyces cerevisiae Proteins | 1 | 2006 | 347 | 0.010 |
Why?
| Models, Genetic | 1 | 2005 | 592 | 0.010 |
Why?
| Pilot Projects | 1 | 2006 | 1405 | 0.010 |
Why?
| Child | 1 | 2020 | 19033 | 0.010 |
Why?
| Computer Simulation | 1 | 2005 | 913 | 0.010 |
Why?
| Case-Control Studies | 1 | 2007 | 3156 | 0.010 |
Why?
| Inflammation | 1 | 2006 | 2545 | 0.010 |
Why?
|
|
Aquilante's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|